SSA
INFI

Schonfeld Strategic Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,600
Closed -$6K – 3281
2022
Q2 		$6K Buy
10,600
+100
+1% +$77 ﹤0.01% 2322
2022
Q1 		$12K Buy
+10,500
New +$12.5K ﹤0.01% 2415
2018
Q2 		– Sell
-278,777
Closed -$585K – 1025
2018
Q1 		$585K Buy
+278,777
New +$598K 0.04% 440

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
MIAN
Mariner Independent Advisor Network Overland Park, Kansas $2.33B AUM 14.85% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schonfeld Strategic Advisors's INFI Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2022, closing a stake of 10,600 shares — an estimated $6K sold.

Schonfeld Strategic Advisors first reported a position in INFI in Q1 2018 and held it in 3 quarters. The position peaked at $585K in Q1 2018. 76 funds tracked by Wall St. Rank hold INFI as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 10,600 Infinity Pharmaceuticals, Inc. shares in Q3 2022, an estimated $6K.
  • Schonfeld Strategic Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Infinity Pharmaceuticals, Inc. position peaked at $585K in Q1 2018.
  • 76 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.